1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Agricultural Inputs
Shaanxi Meibang Pharmaceutical Group Co., Ltd.

Shaanxi Meibang Pharmaceutical Group Co., Ltd.

605033.SS
Shaanxi Meibang Pharmaceutical Group Co., Ltd.CN flagShanghai Stock Exchange
18.11
CNY
+0.01
- -
2.45BMarket Cap
Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS
(Shanghai Stock Exchange)

Recent

price

18.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.69
4.66
5.21
5.63
7.64
6.68
5.22
6.49
6.75
6.1
Revenue per Share
0.68
0.63
0.77
0.78
1.14
1.07
0.43
0.27
0.36
0.4
Basic EPS, GAAP
0.13
-0.19
0.96
0.13
-1.95
0.13
0.98
0.89
0.33
-0.87
Free Cash Flow per Basic Share
0.04
0.04
0.02
0.01
0.03
0.2
0.22
0.21
0.18
0.08
Dividend per Share
1.72
2.01
2.68
3.36
4.49
4.51
4.73
4.66
4.86
5.06
Book Value per Share
1.93
2.84
3.66
4.37
8.7
7.92
7.7
7.37
7.66
7.83
Tangible Book Value per Share
90
94
99
101
110
136
134
137
135
137
Basic Weighted Avg Shares
422
439
516
569
842
906
699
886
912
835
Sales/Revenue/Turnover
18.67
18.47
19.2
16.1
16.5
16.61
8.57
4.19
7.1
11.03
Operating Margin (%)
6
8
10
10
12
15
21
22
33
- -
Depreciation Expense
61
59
76
79
126
145
58
37
49
54
Net Income, GAAP
12.46
11.99
10.82
11.92
9.43
4.78
7.78
2.64
7.08
18.99
Effective Tax Rate (%)
14.51
13.53
14.79
13.85
14.93
16.01
8.23
4.16
5.34
6.5
Profit Margin (%)
107
187
261
295
756
819
611
480
452
626
Working Capital
- -
- -
- -
- -
- -
- -
- -
72
136
147
LT Debt
180
276
371
449
967
1,086
1,114
1,125
1,153
1,189
Total Equity
- -
26.36
24.59
18.68
17.42
13.81
5.04
3.13
4.81
5.77
Return on Invested Capital (%)
- -
30.11
30.29
24.68
29.9
25.78
9.3
5.49
6.46
6.89
Return on Capital (%)
- -
34.54
33.59
26.06
30.15
26.24
9.25
5.81
7.52
7.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
15
11
LT Borrowings
- -
136
147
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
135
135
Market Capitalization
3,025
2,734
3,126

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,157
1,077
Cash, Cash Equivalents & STI
- -
764
583
Accounts Receivable, Net
- -
47
205
Inventories
- -
233
165
Total Current Liabilities
- -
705
451
Payables & Accruals
- -
- -
- -
ST Debt
- -
15
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.71%
2.52%
Free Cash Flow
- -
-249.53%
-63.21%
Net Income, GAAP
- -
2.17%
32.03%
Sales/Revenue/Turnover
- -
12.51%
2.98%
Total Cash Common Dividend
- -
214.56%
-14.68%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
312
198
113
263
886
2025
289
196
- -
303
912
2026
336
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
- -
- -
- -
0.27
2025
0.22
- -
- -
- -
0.36
2026
0.26
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
0.18
2026
- -
- -
- -
- -
- -
Similar Companies
Global Bio-chem Technology Group Company Limited (0809.HK)
Amir Marketing and Investments in Agriculture Ltd (AMRK.TA)
CF Industries Holdings, Inc. (CF)
Sir Shadi Lal Enterprises Limited (SSLEL.BO)
China Green Agriculture, Inc. (CGA)
Danakali Limited (DNKLY)
Business
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS) engages in the research, development, production and sale of pesticide preparations, primarily serving the agricultural sector in China. The company offers a range of fungicides, including 80% dimethylmorpholine water dispersible granules, 27% chunleimycin bromonitrile wettable powder, 72% pyrazole ether ester combined water dispersible granules and 22% chunleimycin chlorobromoisocyanuric acid wettable powder; insecticides, such as 21% abamectin benzoate fenitrile suspension, 22% thiamethoxam beta cypermethrin suspension, 45% biphenyl hydrazide ethiconazole suspension and 20% fenitrile bifenthrin suspension; as well as herbicides, plant growth regulators, fertilizers and microbial fertilizers. Founded in 1998 and headquartered in the High-Tech Industrial Development Zone, Pucheng County, Weinan City, Shaanxi Province, China, the company operates principally within the domestic market with approximately 998 employees. In recent developments, Shaanxi Meibang Pharmaceutical Group invests CNY 50 million in Shaanxi Nuozheng Biotechnology Co., Ltd. to support strategic expansion in biotechnology; reports 2024 revenue of CNY 885.53 million, up 26.68% year-over-year despite a 35.96% decline in net income to CNY 36.86 million; and anticipates first-half 2025 results alongside ongoing compliance with national pesticide registration policies amid stable operations.